RARITAN, N.J., APRIL 30, 2026 – The investigational CD20 mono CAR-T cell therapy and CD19-CD20 bi-CAR-T programs will be discontinued. This is a strategic business decision based on the Company’s portfolio priorities and an assessment of the evolving large B-cell lymphoma treatment landscape.
Patients currently enrolled in these ongoing clinical trials will continue to be supported, per study protocols.
We remain deeply committed to our broad pipeline of pioneering oncology therapies and will continue prioritizing those programs with the greatest potential to transform patient care.